|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Importantly, AKT (also known as protein kinase B), which has been associated with poor prognosis in breast cancer, directly associates with and phosphorylates USP4.
|
22706160 |
2012 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
As a whole, our findings sugggest that USP4 acts as a tumor suppressor in breast cancer and that it may be an effective target for the treatment of breast cancer.
|
27430936 |
2016 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Taken together, the present study provides a novel insight into the regulation of the NF-κB signalling pathway and uncovers a previously unknown function of USP4 in cancer.
|
22029577 |
2012 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
However, the mechanisms and regulatory roles of USP4 in cancer, including colorectal cancer, remain largely elusive.
|
26669864 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Therapies targeting the USP4 inhibits invasion of breast cancer cells via Relaxin/TGF-β1/Smad2/MMP-9 signal.
|
27049265 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our results elucidate that USP4 is highly expressed in HCC and promotes the tumor invasion and metastasis, the underlying mechanism is that USP4 directly interacts with and deubiquitinates TGFR-1 to increase TGF-β signaling-Induced EMT.
|
30335615 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of USP4 diminished colorectal cancer cell growth, colony formation, migration, and invasion in vitro and metastasis in vivo.
|
26669864 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
However, the mechanisms and regulatory roles of USP4 in cancer, including colorectal cancer, remain largely elusive.
|
26669864 |
2016 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Taken together, the present study provides a novel insight into the regulation of the NF-κB signalling pathway and uncovers a previously unknown function of USP4 in cancer.
|
22029577 |
2012 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Among them, USP4 has been proposed as a promising target for colon cancer drugs since USP4 controls the stability of β-catenin, a key factor in the Wnt signaling involved in the tumorigenesis of colorectal cancer.
|
31251006 |
2019 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consistent with this correlation, USP4 knockdown in HCT116, a colon cancer cell line, reduced invasion and migration activity.
|
26189775 |
2015 |
|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We identified NR as an uncompetitive inhibitor of USP4 and validated its effects in colorectal cancer.
|
31251006 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that USP4 is a promising therapeutic target for brain metastasis in patients with lung adenocarcinoma.
|
26883469 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we infer that USP4 expression might be a favorable biomarker in terms of OS and RFS in LUAD patients.
|
29667299 |
2018 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Among them, USP4 has been proposed as a promising target for colon cancer drugs since USP4 controls the stability of β-catenin, a key factor in the Wnt signaling involved in the tumorigenesis of colorectal cancer.
|
31251006 |
2019 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Consistent with this correlation, USP4 knockdown in HCT116, a colon cancer cell line, reduced invasion and migration activity.
|
26189775 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
We identified NR as an uncompetitive inhibitor of USP4 and validated its effects in colorectal cancer.
|
31251006 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, USP4 could be a novel therapeutic target for the treatment of Th17-modulated autoimmune diseases.
|
25821221 |
2015 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Among genes that were most significantly upregulated in carcinomas were 2 ubiquitin-related genes (USP4 and UFD1L) and several insulinlike growth factor-related genes (IGF2, IGF2R, IGFBP3 and IGFBP6).
|
16360395 |
2005 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, our study uncovered a previously unknown function of USP4 in esophageal cancer and more investigations would be carried out to further study its regulation gene network and molecular biological mechanism in esophageal cancer.
|
28946564 |
2017 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hepatocyte-specific USP4 depletion exacerbated HS, IR, and inflammatory response in HFD-induced NAFLD mice.
|
29573006 |
2018 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
USP4 knockout mice exhibited exacerbated hepatic I/R injury, as evidenced by enhanced liver inflammation via the nuclear factor κB (NF-κB) signalling pathway and increased hepatocyte apoptosis.
|
30622220 |
2019 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our results demonstrate that the up-regulated USP4 plays an oncogenic role in melanoma by simultaneously suppressing stress-induced cell apoptosis and facilitating tumour metastasis.
|
29542252 |
2018 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Conclusion: Collectively, the present study provides evidence that USP4 functions as a pivotal suppressor in NAFLD and related metabolic disorders.(Hepatology 2018; 00:000-000).
|
29573006 |
2018 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our study uncovered a previously unknown function of USP4 in esophageal cancer and more investigations would be carried out to further study its regulation gene network and molecular biological mechanism in esophageal cancer.
|
28946564 |
2017 |